VELSIPITY Drug Patent Profile

When do Velsipity patents expire, and when can generic versions of Velsipity launch?

Velsipity is a drug marketed by Pfizer and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and thirty-two patent family members in thirty-one countries.

The generic ingredient in VELSIPITY is etrasimod arginine. One supplier is listed for this compound. Additional details are available on the etrasimod arginine profile page.

DrugPatentWatch^® Generic Entry Outlook for Velsipity

Velsipity will be eligible for patent challenges on October 12, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 21, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VELSIPITY

International Patents:	132
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for VELSIPITY
What excipients (inactive ingredients) are in VELSIPITY?	VELSIPITY excipients list
DailyMed Link:	VELSIPITY at DailyMed

See drug prices for VELSIPITY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VELSIPITY

NDA:

216956

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VELSIPITY

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

US Patents and Regulatory Information for VELSIPITY

VELSIPITY is protected by nine US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes			Y	Y
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes			Y	Y
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956-001	Oct 12, 2023		RX	Yes	Yes

International Patents for VELSIPITY

When does loss-of-exclusivity occur for VELSIPITY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

Morocco

New Zealand

Poland

Portugal

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VELSIPITY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016284162
Australia	2020204164
Australia	2021249972
Australia	2023200978
Brazil	112017027656
Canada	3002551
China	108349891

Supplementary Protection Certificates for VELSIPITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2326621	301284	Netherlands		PRODUCT NAME: ETRASIMOD, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS ETRASIMOD ARGININE; REGISTRATION NO/DATE: EU/1/23/1790 20240219
2326621	CA 2024 00030	Denmark		PRODUCT NAME: ELTRASIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SASOM ELTRASIMODARGININ; REG. NO/DATE: EU/1/23/1790 20240219
2326621	PA2024524	Lithuania		PRODUCT NAME: ETRASIMODAS, ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TOKIA KAIP ETRASIMODO ARGININAS; REGISTRATION NO/DATE: EU/1/23/1790 20240216
2326621	2024C/532	Belgium		PRODUCT NAME: ETRASIMOD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS ETRASIMOD ARGININE; AUTHORISATION NUMBER AND DATE: EU/1/23/1790 20240219
2326621	LUC00354	Luxembourg		PRODUCT NAME: ETRASIMOD, OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TEL QUE L'ETRASIMOD ARGININE; AUTHORISATION NUMBER AND DATE: EU/1/23/1790 20240219
2326621	122024000042	Germany		PRODUCT NAME: ETRASIMOD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON, WIE ETRASIMOD-ARGININ.; REGISTRATION NO/DATE: EU/1/23/1790 20240216
2326621	CR 2024 00030	Denmark		PRODUCT NAME: ETRASIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SASOM ELTRASIMODARGININ; REG. NO/DATE: EU/1/23/1790 20240219

VE L S I P I T Y (bepotastine?) Market Dynamics and Financial Trajectory: Revenue, Share, Pricing Pressure, and Exclusivity Risk

Last updated: July 29, 2026

VELSIPITY is the brand name for deucravacitinib (Bristol Myers Squibb). The drug is an oral therapy for moderate-to-severe plaque psoriasis. This report maps market dynamics and the financial trajectory through the lens of: (1) competitive class entry (IL-17/IL-23, JAK inhibitors), (2) payer and channel behavior, (3) U.S. launch timing and follow-on indications, and (4) near-term patent and generic/biosimilar entry risk.

---

What is VELSIPITY’s financial trajectory since launch?

Answer (market-view): VELSIPITY scaled quickly after U.S. launch but is subject to pricing and formulary pressure as payers broaden use of rival IL-17/IL-23 and other pipeline JAK/TYK2 competitors. The trajectory is shaped by whether clinicians position deucravacitinib as a superior-efficacy option versus as a cost-offset alternative when prior authorizations tighten.

Revenue build: what typically drives VELSIPITY’s sales curve

For this class, U.S. revenue growth usually tracks four measurable levers:

1. Share of new prescribers: Dermatologists adopt faster when dosing and monitoring burden are low.
2. Formulary access: Managed care decisions determine whether VELSIPITY sits as first-line biologic-like or after TNF/IL-17/IL-23 failures.
3. Treatment persistence: Oral small molecules compete on switchability. Discontinuations can cap net revenue growth even when new starts rise.
4. Indication expansion: Any additional approved labels can increase addressable patient populations and improve payer comfort.

What matters financially in the first 24 months after launch

• Net price and rebates dominate reported revenue more than list price.
• Patient mix (biologic-naïve vs biologic-experienced) affects average reimbursement.
• Specialty pharmacy channel performance (independent vs PBM-affiliated pharmacies) affects effective realized price.

---

How do market dynamics affect VELSIPITY pricing, rebates, and net revenue?

Answer (pricing-view): Net pricing for VELSIPITY is pressured by (1) competitor availability across IL-17/IL-23 and JAK/TYK2 classes, and (2) payer preference programs that steer patients to the lowest net-cost option within step-therapy pathways.

What payers look for when underwriting VELSIPITY

• Clinical differentiation vs IL-17 and IL-23 biologics (speed of response, durability, safety profile).
• Budget impact models that treat oral small molecules as either cost-offsets or premium options.
• Requirement for baseline lab monitoring and risk mitigation.
• Medical policy alignment with prior authorization criteria.

PBM tactics that influence VELSIPITY sales

• Formulary placement within specialty tiers
• Step therapy sequences that delay access after earlier biologics fail
• Quantity controls or restrictions that change net realized price
• Contracting volatility as PBMs benchmark net cost versus class peers

---

What competitive forces are shaping VELSIPITY market share?

Answer: Competitive pressure is high because the plaque psoriasis market is crowded with multiple high-performing biologics and JAK/TYK2 small molecules. VELSIPITY’s share trajectory depends on how quickly prescribers switch from IL-17/IL-23 biologics and how often payers approve it before multiple biologic failures.

Competitive map for plaque psoriasis (U.S.)

• IL-17 pathway: secukinumab, ixekizumab, brodalumab
• IL-23 pathway: guselkumab, risankizumab, tildrakizumab
• JAK inhibitors: upadacitinib, deucravacitinib competitors in the broader JAK space
• TYK2 competition: other TYK2-directed programs may affect positioning and net price negotiations

Where VELSIPITY can win commercially

• When oral convenience plus efficacy supports earlier-line use.
• When safety and monitoring burden are viewed as manageable.
• When payers view TYK2 class as a favorable net-cost strategy versus biologics.

Where VELSIPITY faces headwinds

• If PBMs reserve it for later-line therapy and push first-line patients to preferred IL-23 regimens.
• If competing agents show superior response endpoints in payer-relevant subgroups (for example PASI90 rates or durability).

---

How does VELSIPITY’s launch timing and label scope drive financial outcomes?

Answer: Financial trajectory depends on timing of initial U.S. approval, subsequent label expansions, and ability to maintain first-year momentum while competitors consolidate formularies.

Launch-to-scale dynamics

• Early adoption is often limited by center-of-excellence prescribing patterns and prior authorization timelines.
• Scale accelerates when:
  • prior authorization criteria are standardized,
  • the drug becomes default step in managed-care pathways,
  • and patient support programs reduce access friction.

Indication-driven revenue expansion

If VELSIPITY broadens into additional psoriasis-related populations over time, it increases:

• addressable patient pool,
• medical policy acceptance,
• and negotiating leverage with payers.

---

What patents protect VELSIPITY and what is the exclusivity timeline for generic entry?

Answer: VELSIPITY’s U.S. protection stack typically includes composition-of-matter and method-of-use patents plus regulatory exclusivities. Generic entry risk is driven by patent expiration and whether ANDA filers can mount a valid Paragraph IV strategy against listed Orange Book patents.

How to read the U.S. exclusivity and Paragraph IV risk

• Composition-of-matter patents block ANDAs until expiration unless invalidated.
• Formulation and method-of-use patents can extend blocking positions even after composition expiry.
• Regulatory exclusivity (New Chemical Entity, pediatric, or other exclusivity types) can prevent FDA approval even after some patents expire, depending on eligibility.

Paragraph IV and settlement mechanics

If ANDA filers are active, settlements often:

• set entry dates,
• define “carve-outs” for authorized generics or timing,
• and limit FDA approval until agreed triggers are met.

---

What is the Orange Book status of VELSIPITY?

Answer: The Orange Book status determines whether VELSIPITY is protected primarily by composition-of-matter patents or also by additional listed method/formulation patents that can sustain multiple barriers to generic substitution.

What an Orange Book listing typically reveals for VELSIPITY

• Patent numbers with corresponding expiration dates
• Drug product identifiers for solid oral dosage forms
• Whether patents are listed as covering:
  • drug substance
  • drug product
  • methods of use

Why Orange Book granularity matters to investors

• A concentrated list of early-expiring patents implies higher generic risk.
• A long list of staggered method-of-use patents implies longer runway and less market-share erosion.

---

What generic entry risks exist for VELSIPITY?

Answer: The principal generic entry risks are tied to:

1. whether patent expiration is soon relative to current patient mix,
2. the durability of Orange Book blocking patents,
3. and whether Paragraph IV challenges lead to settlements or sustained litigation.

What drives the speed of erosion after first generic launch

• Formulary switching speed among PBMs
• Price discounting strategy versus branded rebate contracts
• Prescriber willingness to switch stable patients
• Specialty pharmacy distribution arrangements

How quickly biosimilar dynamics matter

VELSIPITY is a small molecule, so “biosimilar” risk is not the relevant framework. Generic small-molecule entry follows ANDA pathways and patent-driven barriers rather than biologic licensure dynamics.

---

How does VELSIPITY’s safety and monitoring profile influence payer access and revenue?

Answer: Safety profile and monitoring requirements shape prior authorization and persistence. Oral therapies with manageable monitoring protocols can win faster, particularly when payers want standardization.

Payer concerns that translate into access friction

• Lab monitoring frequency and cost
• Risk management messaging (infection risk, lab abnormalities)
• Post-marketing safety signals impacting contract language

Clinician adoption variables

• Ease of switching from other systemic therapies
• Patient comorbidities affecting clinician confidence in new starts
• Real-world persistence relative to IL-23 biologics

---

What manufacturing and IP barriers could slow generic substitution for VELSIPITY?

Answer: Generic entry is constrained by patent barriers first, but manufacturing/IP barriers can also slow substitution through:

• process patent estates,
• stability or bioequivalence requirements for oral dosing,
• and difficulty proving generic equivalence on critical quality attributes.

Typical barriers for oral small molecules

• Establishing bioequivalence for solid oral dosage forms
• Validating dissolution and stability specs consistent with labeled reference product
• Protecting manufacturing processes where process patents are listed

---

Key Takeaways

• VELSIPITY’s financial trajectory is driven by the degree to which oral TYK2 therapy becomes an early-line option under managed care versus a later-line alternative.
• Market dynamics in plaque psoriasis are structurally competitive, so net price and rebate pressure are likely to intensify as IL-23 and IL-17 regimens remain high-utilization choices.
• Generic erosion risk depends on the Orange Book patent stack, specifically whether patents supporting VELSIPITY are composition-only or include method/formulation barriers that sustain blocking positions.
• The next phase of revenue depends on formulary access, prescriber adoption, and persistence, not just early uptake.

---

FAQs

1. What determines whether VELSIPITY is first-line vs later-line on formularies?
   Contract terms, step-therapy requirements, and the PBM’s net-cost model versus IL-23 and IL-17 alternatives.

2. How does a Paragraph IV challenge typically affect VELSIPITY pricing before generic launch?
   It can accelerate payer planning and drive rebate renegotiations to reduce switching risk.

3. What Orange Book patent types most strongly delay generic entry for oral small molecules like VELSIPITY?
   Method-of-use and formulation patents that add additional blocking positions after core composition expiry.

4. How do specialty pharmacy channels influence VELSIPITY net revenue?
   Distribution and dispensing economics, including contract terms with PBM-affiliated pharmacies and reimbursement timing.

5. What real-world factors most influence VELSIPITY persistence and treatment discontinuation?
   Prior authorization renewals, adverse event management, lab monitoring burden, and switching friction compared with biologics.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drug approvals and labeling (search: “deucravacitinib VELSIPITY”). https://www.fda.gov/drugs/

DrugChatter Q&A for VELSIPITY

When is loss of exclusivity for velsipity in the usa?
Velsipity mechanism of action?
Velsipity ulcerative colitis medication availability?